Alosetron HCl - CAS 122852-69-1
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alosetron HCl
Catalog Number:
122852-69-1
Synonyms:
2,3,4,5-Tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1H-pyrido[4,3-b]indol-1-one Hydrochloride;
CAS Number:
122852-69-1
Description:
The hydrochloride salt form of Alosetron which is an effective 5-HT3 receptor antagonist and could be commonly used against irritable bowel syndrome.
Molecular Weight:
330.81
Molecular Formula:
C17H18N4O. HCl
Quantity:
Milligrams-Grams
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C.Cl
InChI:
InChI=1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H
InChIKey:
FNYQZOVOVDSGJH-UHFFFAOYSA-N
Targets:
5-HT Receptor
Chemical Structure
CAS 122852-69-1 Alosetron HCl

Related 5-HT Receptor Products


CAS 27833-64-3 Loxapine Succinate

Loxapine Succinate
(CAS: 27833-64-3)

Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.oxapine is a typical antipsych...

SUVN-502
(CAS: 701205-60-9)

SUVN-502 is a 5-HT6 receptor antagonist originated by Suven Life Sciences. It has >1200-fold selectivity over 5-HT2A receptor with a superior profile that diffe...

CAS 112885-42-4 Mosapride Citrate

Mosapride Citrate
(CAS: 112885-42-4)

Mosapride Citrate is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

CAS 58-39-9 Perphenazine

Perphenazine
(CAS: 58-39-9)

Perphenazine is a typical antipsychotic. a piperazinyl phenothiazine, used to treat psychosis

CP-809101 hydrochloride
(CAS: 1215721-40-6)

The hydrochloride salt form of CP-809101 which is a selective 5-HT2C receptor agonist which probably shows antipsychotic activity and restrains amphetamine-stim...

MK212 hydrochloride
(CAS: 61655-58-1)

MK212 hydrochloride is a selective 5-HT2C serotonin receptor agonist. It displays selectivity for 5-HT2C over 5-HT2A with IC50 values of 0.028 and 0.42 μM for h...

CAS 15574-96-6 Pizotifen

Pizotifen
(CAS: 15574-96-6)

Pizotifen, also called as BC 105, a benzocycloheptathiophene derivative that is a highly selective 5-HT receptor blocking agent both in vivo (on saphenous veins...

CAS 199864-87-4 RS 127445

RS 127445
(CAS: 199864-87-4)

RS 127445 is a high affinity, orally bioavailable, selective serotonin antagonist of 5-HT2B receptor (pIC50= 10.4) with 1000 fold selectivity over the human rec...

CAS 361-37-5 Methysergide

Methysergide
(CAS: 361-37-5)

Methysergide is an ergot derivative that is a congener of lysergic acid diethylamide for the treatment of vascular headache

CAS 18016-80-3 Lisuride

Lisuride
(CAS: 18016-80-3)

Lisuride, an indoloquinoline derivative, has been found to be a dopamine D2 receptor agonist and could probably be effective in antimigraine as well as antipark...

CAS 103628-48-4 Sumatriptan Succinate

Sumatriptan Succinate
(CAS: 103628-48-4)

Sumatriptan Succinate is a triptan sulfa drug containing a sulfonamide group for the treatment of migraine headaches.

LY 125180
(CAS: 74515-39-2)

LY 125180 is a serotonin antagonist.It can effect on serotonin uptake and serotonin synthesis in rat brain in vitro and in vivo.

CAS 152811-62-6 Piboserod

Piboserod
(CAS: 152811-62-6)

Piboserod is a highly and potent selective 5-HT4 receptor antagonist which as been studied in vitro as well as in vivo as a pharmacological tool to evaluate the...

CAS 1049747-87-6 SB-242084 HCl salt

SB-242084 HCl salt
(CAS: 1049747-87-6)

SB-242084 is a psychoactive drug and research chemical which acts as a selective antagonist for the 5HT2C receptor. It can increase the effectiveness of the sel...

CAS 135159-51-2 Sarpogrelate hydrochloride

Sarpogrelate hydrochloride
(CAS: 135159-51-2)

The hydrochloride salt form of Sarpogrelate, a 5-HT2 antagonist, could be used as an antiplatelet agent and other sorts of disease like angina pectoris, diabete...

CAS 57477-39-1 BRL-54443

BRL-54443
(CAS: 57477-39-1)

BRL 54443 is a 5-HT1E and 5-HT1F receptor agonist with pKi of 8.7 and 9.25, respectively, with a weak binding affinity for 5-HT1A, 5-HT1B, 5-HT1D receptors.

RU-24969
(CAS: 66611-26-5)

RU 24969 is a 5-HT1A and 5-HT1B receptors act as serotonin 1A/1B receptor agonists.

CAS 479683-64-2 CP 809101 hydrochloride

CP 809101 hydrochloride
(CAS: 479683-64-2)

CP-809101 is a potent and selective 5-HT2C receptor agonist (pEC50=9.96).

CAS 107007-99-8 Granisetron HCl

Granisetron HCl
(CAS: 107007-99-8)

Granisetron HCl is a serotonin 5-HT3 receptor antagonist.

CAS 121679-13-8 Naratriptan

Naratriptan
(CAS: 121679-13-8)

Naratriptan, a 5-HT1B/1D receptor agonist, could be used in the treatment of migraine.

Reference Reading


1.Development of a Forced Degradation Profile of Alosetron by Single Mode Reversed-Phase HPLC, LC-MS, and its Validation.
Karthik Y1, Babu B1, Meyyanathan SN1. Sci Pharm. 2014 Dec 29;83(2):311-20. doi: 10.3797/scipharm.1411-07. eCollection 2015.
Determination of alosetron in the presence of its degradation products was studied and validated by a novel HPLC method. The separation of the drug and its degradation products was achieved with the Jones Chromatography C18 analytical column (150 mm x 4.6 mm; 3 µm) with a stationary phase in isocratic elution mode. The mobile phase used was 0.01 M ammonium acetate, pH-adjusted to 3.5 with glacial acetic acid and acetonitrile in the ratio of 75:25 (V/V) at a flow rate of 1 ml/min and UV detection was carried out at 217 nm. Further, the drug was subjected to stress studies for acidic, basic, neutral, oxidative, and thermal degradations as per ICH guidelines and the drug was found to be labile in base hydrolysis and oxidation, while stable in acid, neutral, thermal, and photolytic degradation conditions. An MS study has been performed on the major degradation products to predict the degradation pathway of alosetron. The method provided linear responses over the concentration range of 100-1500 ng/ml and regression analysis showed a correlation coefficient value (r(2)) of 0.
2.Novel pharmacological therapies for irritable bowel syndrome.
Corsetti M1, Whorwell P2. Expert Rev Gastroenterol Hepatol. 2016 Mar 18:1-9. [Epub ahead of print]
Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder, which represents a major cost to healthcare services. Current pharmacological treatment includes fibre supplements, antispasmodics, laxatives, loperamide and antidepressants. This article reviews the novel pharmacological treatments already or recently approved for patients with IBS-C (lubiprostone, linaclotide) and IBS-D (alosetron, ramosetron, rifaximin, eluxadoline). Furthermore, results for drugs in development (plecanatide, ibudutant and ebastine) or used in chronic constipation or for other indications, with potential application in IBS (prucalopride, elobixibat, mesalazine, ondansetron and colesevelam) are also reviewed.
3.Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome.
Lacy BE1. Int J Gen Med. 2016 Feb 11;9:7-17. doi: 10.2147/IJGM.S93698. eCollection 2016.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders worldwide. The economic impact of IBS on the health care system is substantial, as is the personal impact on patients. Patients with diarrhea-predominant IBS (IBS-D) comprise a substantial proportion of the overall IBS population. Primary care providers are often the first point of contact for patients with IBS-D and can accurately diagnose IBS after a careful history and examination without extensive diagnostic tests. Several pharmacologic treatments (eg, loperamide, alosetron, and antidepressants) and non-pharmacologic treatments (eg, dietary modification and probiotics) are available for IBS-D, but restrictions on use (eg, alosetron) or the lack of controlled trial data showing reductions in both global and individual IBS-D symptoms (eg, bloating, pain and stool frequency) emphasize the need for alternative treatment options. Two newer medications (eluxadoline and rifaximin) were approved in May 2015 for the treatment of IBS-D, and represent new treatment options for this common gastrointestinal condition.
4.Novel Therapies in IBS-D Treatment.
Nee J1, Zakari M2, Lembo AJ2. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5.
OPINION STATEMENT: Irritable bowel syndrome (IBS) is a common gastrointestinal disease characterized by abdominal pain and change in bowel habits. IBS diarrhea predominant (IBS-D), which is arguably the most common subset of IBS, is also associated with rectal urgency, increased frequency, abdominal bloating, and loose to watery stools. Current treatments for diarrhea include mu-opioid agonists (i.e., loperamide, lomotil) and bile acid sequestrants (i.e., cholestyramine) while treatments for abdominal pain include antispasmodics (i.e., hyoscyamine, dicyclomine) and tricyclic antidepressants (i.e., amitriptyline). There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Alosetron was initially approved by FDA 2000; however, its use is now limited to women with severe IBS-D symptoms refractory to other treatment. Eluxadoline, a mixed mu-opioid agonist, and rifaximin, a broad spectrum gut specific antibiotic, were both FDA approved in 2015.